<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01020994</url>
  </required_header>
  <id_info>
    <org_study_id>H 552 000 - 0911</org_study_id>
    <secondary_id>EudraCT: 2009-011931-11</secondary_id>
    <nct_id>NCT01020994</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of LAS41003 in the Treatment of Superficial Infected Eczema</brief_title>
  <official_title>Explorative, Double-blind, Randomized, Controlled Multi-center Phase II Study to Evaluate the Efficacy and Safety of Topically Applied LAS41003 Once Daily Versus LAS189962 and LAS189961 in the Treatment of Superficial Infected Eczema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Almirall, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Almirall, S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determine the efficacy and safety of topical application of
      LAS41003 in comparison to LAS189962 and LAS189961 in the treatment of superinfected eczema.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combination of clinical and microbial treatment success</measure>
    <time_frame>Day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety:Physical examination at EoT, AEs/SAEs during the entire study</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Eczema</condition>
  <arm_group>
    <arm_group_label>LAS41003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LAS189962</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LAS189961</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS41003</intervention_name>
    <description>Once daily, topically</description>
    <arm_group_label>LAS41003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS189962</intervention_name>
    <description>Once daily, topically</description>
    <arm_group_label>LAS189962</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS189961</intervention_name>
    <description>Once daily, topically</description>
    <arm_group_label>LAS189961</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically diagnosed super-infected or impetiginized eczema

        Exclusion Criteria:

          -  Patients who have general signs of systemic infections like fever, malaise,
             lymphangitis or swollen lymph nodes and / or need systemic antibiotic treatment

          -  Patients who have a bacterial skin infection which, due to depth and severity, could
             not be appropriately treated with a topical antimicrobial or antiseptic medication

          -  Diagnose of the following disease:

               -  Known active tuberculosis or any history of past tuberculosis of skin

               -  Suspected or proven parasitic infection of the treatment site (e.g. scabies)

               -  Psoriasis

               -  Suspected or proven viral infection of skin (e.g. Herpes)

          -  Localization of the superficial infected eczema:

               -  Palms of the hands

               -  Sole of a foot

               -  Face

          -  Have received any topical treatment with antibiotics, antimycotics, immunomodulators
             and corticosteroid preparations within the last 2 weeks before treatment with IMP
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Willers, MD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Almirall Hermal GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2009</study_first_submitted>
  <study_first_submitted_qc>November 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2009</study_first_posted>
  <last_update_submitted>July 8, 2010</last_update_submitted>
  <last_update_submitted_qc>July 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Head of Global Clinical Development</name_title>
    <organization>Almirall Hermal GmbH</organization>
  </responsible_party>
  <keyword>Superficial infected eczema</keyword>
  <keyword>Superinfected eczema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

